Next Article in Journal
Altered Plasma Acylcarnitines and Amino Acids Profile in Spinocerebellar Ataxia Type 7
Next Article in Special Issue
Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson’s Disease: A New Therapeutic Strategy
Previous Article in Journal
Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases
Previous Article in Special Issue
The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
Open AccessFeature PaperReview

Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts

1
Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
2
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(3), 391; https://doi.org/10.3390/biom10030391
Received: 29 January 2020 / Revised: 26 February 2020 / Accepted: 29 February 2020 / Published: 3 March 2020
Parkinson’s Disease (PD) is characterized both by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy Bodies. These Lewy Bodies contain the aggregated α-synuclein (α-syn) protein, which has been shown to be able to propagate from cell to cell and throughout different regions in the brain. Due to its central role in the pathology and the lack of a curative treatment for PD, an increasing number of studies have aimed at targeting this protein for therapeutics. Here, we reviewed and discussed the many different approaches that have been studied to inhibit α-syn accumulation via direct and indirect targeting. These analyses have led to the generation of multiple clinical trials that are either completed or currently active. These clinical trials and the current preclinical studies must still face obstacles ahead, but give hope of finding a therapy for PD with time. View Full-Text
Keywords: Parkinson’s disease; α-synuclein; neurodegeneration; therapy; aggregation Parkinson’s disease; α-synuclein; neurodegeneration; therapy; aggregation
MDPI and ACS Style

Teil, M.; Arotcarena, M.-L.; Faggiani, E.; Laferriere, F.; Bezard, E.; Dehay, B. Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts. Biomolecules 2020, 10, 391.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop